[go: up one dir, main page]

AU2001232002A1 - Blockade of voltage dependent sodium channels - Google Patents

Blockade of voltage dependent sodium channels

Info

Publication number
AU2001232002A1
AU2001232002A1 AU2001232002A AU3200201A AU2001232002A1 AU 2001232002 A1 AU2001232002 A1 AU 2001232002A1 AU 2001232002 A AU2001232002 A AU 2001232002A AU 3200201 A AU3200201 A AU 3200201A AU 2001232002 A1 AU2001232002 A1 AU 2001232002A1
Authority
AU
Australia
Prior art keywords
sodium channels
blockade
dependent sodium
voltage dependent
voltage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232002A
Inventor
Gitti Garthwaite
Marcel Kling
David Selwood
Grant Wishart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Publication of AU2001232002A1 publication Critical patent/AU2001232002A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds of Formula I and pharmaceutically acceptable salts thereof, are capable of blockading voltage-dependent sodium channels and are useful in particular, in treating glaucoma and multiple sclerosis.
AU2001232002A 2000-02-04 2001-02-05 Blockade of voltage dependent sodium channels Abandoned AU2001232002A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0002666.6A GB0002666D0 (en) 2000-02-04 2000-02-04 Blockade of voltage dependent sodium channels
GB0002666 2000-02-04
PCT/GB2001/000472 WO2001057024A1 (en) 2000-02-04 2001-02-05 Blockade of voltage dependent sodium channels

Publications (1)

Publication Number Publication Date
AU2001232002A1 true AU2001232002A1 (en) 2001-08-14

Family

ID=9885029

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232002A Abandoned AU2001232002A1 (en) 2000-02-04 2001-02-05 Blockade of voltage dependent sodium channels

Country Status (8)

Country Link
US (2) US7009056B2 (en)
EP (1) EP1252156B1 (en)
AT (1) ATE508127T1 (en)
AU (1) AU2001232002A1 (en)
DE (1) DE60144554D1 (en)
ES (1) ES2362859T3 (en)
GB (1) GB0002666D0 (en)
WO (1) WO2001057024A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324721A1 (en) 1996-09-23 2009-12-31 Jack Kennedy Hydrogels Suitable For Use In Polyp Removal
AR032653A1 (en) * 2001-02-09 2003-11-19 Telik Inc HYPERCYCLIC INHIBITORS OF THE GLICINE TRANSPORTER 2 PHARMACEUTICAL COMPOSITIONS, USE AND METHODS.
US6982274B2 (en) 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
GB0120238D0 (en) * 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
DE10149370A1 (en) * 2001-10-06 2003-04-10 Merck Patent Gmbh New 1-(phenyl or pyridinyl)-1H-pyrazole derivatives, are glycine transporter inhibitors useful e.g. for treating schizophrenia, depression, dementia, neurodegenerative diseases or pain
EP1506196B1 (en) * 2001-11-01 2012-01-18 Icagen, Inc. Pyrazolopyrimidines as sodium channel inhibitors
TWI264304B (en) 2002-01-25 2006-10-21 Yung Shin Pharm Ind Co Ltd Methods of treating sepsis
US20050209252A1 (en) * 2002-03-29 2005-09-22 Che-Ming Teng Cancer treatment
US7166293B2 (en) * 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
DE10216145A1 (en) * 2002-04-12 2003-10-23 Bayer Ag Use of stimulators of soluble guanylate cyclase to produce a medicament for treating glaucoma
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
CN100436445C (en) * 2003-02-07 2008-11-26 第一制药株式会社 Pyrazole derivatives
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7226941B2 (en) * 2003-06-30 2007-06-05 Hif Bio, Inc. Compound for treating angiogenesis
CA2534221A1 (en) * 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
WO2005040161A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
US7663524B2 (en) * 2003-11-13 2010-02-16 Silicon Touch Technology Inc. Multi-channel display driver circuit incorporating modified D/A converters
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US7378532B2 (en) * 2004-03-26 2008-05-27 Yung Shin Pharmaceutical Ind. Co., Ltd. Fused pyrazolyl compound
EP1794130A1 (en) * 2004-09-20 2007-06-13 Biolipox AB Pyrazole compounds useful in the treatment of inflammation
JP2008513426A (en) * 2004-09-20 2008-05-01 バイオリポックス エービー Pyrazole compounds useful for the treatment of inflammation
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
MX2007006408A (en) 2004-11-29 2007-06-22 Warner Lambert Co Therapeutic pyrazolo[3,4-b] pyridines and indazoles.
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US8067638B2 (en) 2005-06-21 2011-11-29 Mitsui Chemicals, Inc. Amide derivative and insecticide containing the same
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
AU2006310367A1 (en) * 2005-10-31 2007-05-10 Biolipox Ab Triazole compounds as lipoxygenase inhibitors
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009513692A (en) * 2005-11-01 2009-04-02 バイオリポックス エービー Pyrazole compounds useful for the treatment of inflammation
US8186555B2 (en) 2006-01-31 2012-05-29 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting and fastening instrument with mechanical closure system
DE102006020327A1 (en) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclic substituted, fused pyrazole derivatives and their use
DE102006021733A1 (en) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-tetrazolylindazoles and 3-tetrazolylpyrazolopyridines and their use
DE102006043443A1 (en) 2006-09-15 2008-03-27 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
US20090005809A1 (en) 2007-03-15 2009-01-01 Hess Christopher J Surgical staple having a slidable crown
GEP20125379B (en) * 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
BRPI0812361A2 (en) 2007-05-18 2015-02-03 Bayer Schering Pharma Ag Heteroaryl PIRAZOL DERIVATIVES SUBSTITUTED FOR THE TREATMENT OF ANGIOGENESE DISORDERS AND HYPERPROLIFERATIVE DISEASES
DE102008063992A1 (en) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. New aliphatic substituted pyrazolopyridines and their use
GB0917238D0 (en) 2009-10-01 2009-11-18 Univ London Blockade of voltage dependent sodium channels
US20110172428A1 (en) * 2010-01-12 2011-07-14 Shan-Ming Kuang Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt
DE102010021637A1 (en) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituted 5-fluoro-1H-pyrazolopyridines and their use
WO2011158108A2 (en) * 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
US8921401B2 (en) 2013-02-07 2014-12-30 Musc Foundation For Research Development Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
KR20150119871A (en) 2013-02-21 2015-10-26 아드베리오 파마 게엠베하 Methyl {4,6-diamino-2- [1- (2-fluorobenzyl) -1H-pyrazolo [3,4- b] pyridino-3-yl] pyrimidino- The shape of the bar mate
US9844368B2 (en) 2013-04-16 2017-12-19 Ethicon Llc Surgical system comprising first and second drive systems
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN110627767B (en) * 2019-09-05 2020-08-25 中国药科大学 Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof
CN116438162A (en) * 2020-09-17 2023-07-14 伊赛恩特制药公司 Modulators of MAS-associated G protein receptor X4 and related products and methods
WO2022263498A1 (en) * 2021-06-15 2022-12-22 Grünenthal GmbH Substituted pyrazole amides
CN113929627A (en) * 2021-10-19 2022-01-14 吕梁学院 Synthetic method of bindarit

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662692B1 (en) * 1990-05-30 1995-04-28 Novapharme HETEROCYCLIC DERIVATIVES WITH ANTICONVULSIVE ACTIVITY, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION.
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
FR2714057B1 (en) * 1993-12-17 1996-03-08 Sanofi Elf New derivatives of 3-pyrazolecarboxamide, process for their preparation and pharmaceutical compositions containing them.
JP2928079B2 (en) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1- (Substituted benzyl) -3- (substituted aryl) condensed pyrazoles, their production and use
CN1177354A (en) * 1995-03-02 1998-03-25 法玛西雅厄普约翰美国公司 Pyrimido [4, 5 -b] indoles
DE19642255A1 (en) * 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
DE19642323A1 (en) * 1996-10-14 1998-04-16 Bayer Ag New 1-substituted-(substituted (hetero)aryl)- fused pyrazole compounds
DE19701277A1 (en) * 1997-01-16 1998-07-23 Bayer Ag Process for the preparation of 1-alkyl-pyrazole-5-carboxylic acid esters
US5922746A (en) 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
AU754681B2 (en) 1998-02-04 2002-11-21 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
DE19834714A1 (en) * 1998-07-31 2000-02-03 Boehringer Ingelheim Pharma New 2,3,3a, 4,9,9a-hexahydro-8-hydroxy-1H-ben [f] indoles, process for their preparation and their use as pharmaceuticals
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists

Also Published As

Publication number Publication date
EP1252156A1 (en) 2002-10-30
WO2001057024A1 (en) 2001-08-09
US7009056B2 (en) 2006-03-07
US20030171403A1 (en) 2003-09-11
ATE508127T1 (en) 2011-05-15
DE60144554D1 (en) 2011-06-16
ES2362859T3 (en) 2011-07-14
US20060100248A1 (en) 2006-05-11
EP1252156B1 (en) 2011-05-04
US7790761B2 (en) 2010-09-07
GB0002666D0 (en) 2000-03-29

Similar Documents

Publication Publication Date Title
AU2001232002A1 (en) Blockade of voltage dependent sodium channels
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
AU3850600A (en) Dalda analogs and their use
AU5986200A (en) Compounds
MY119403A (en) Novel compounds with analgesic effect.
WO2002050061A8 (en) Piperazine derivatives for treatment of bacterial infections
AU4257901A (en) Triarylimidazole derivatives as cytokine inhibitors
WO2003010138A3 (en) Piperidine derivatives as antibacterial agents
MY132705A (en) Novel compounds with analgesic effect
GB9822450D0 (en) Medicaments
GB0101577D0 (en) Compounds
YU69902A (en) New piperazine derivatives
SE9802208D0 (en) Novel compounds
WO2003051275A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
UA86776C2 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0300908D0 (en) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
AU5705099A (en) Compounds useful as aicarft inhibitors
AU2002359150A1 (en) Therapeutic heterocycles
AU7270798A (en) Antithrombotic agents
SE9802209D0 (en) Novel compounds
SE9504662D0 (en) New compounds
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
AU2001296677A1 (en) Substituted (e)-styryl benzylsulfones for treating proliferative disorders
ATE250610T1 (en) POTASSIUM CHANNEL BLOCKING AGENTS
ATE286395T1 (en) ANTITHRBOTIC AGENTS